Modality
Bispecific Ab
MOA
PRMT5i
Target
DLL3
Pathway
Neuroinflam
AS
Development Pipeline
Preclinical
~Jul 2019
→ ~Oct 2020
Phase 1
~Jan 2021
→ ~Apr 2022
Phase 2
Jul 2022
→ Sep 2031
Phase 2Current
NCT06058710
1,096 pts·AS
2022-07→TBD·Completed
NCT03771332
2,115 pts·AS
2025-11→2031-09·Completed
3,211 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-09-125.5y awayPh2 Data· AS
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Complet…
P2
Complet…
Catalysts
Ph2 Data
2031-09-12 · 5.5y away
AS
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06058710 | Phase 2 | AS | Completed | 1096 | EDSS |
| NCT03771332 | Phase 2 | AS | Completed | 2115 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C |